Several studies in normal cells, cancer and disease models have previously identified chemicals that activate or block the RNAse and/or kinase activity of IRE1ɑ and modulate the Xbp1s:Xbp1u ratio as potential therapeutic modifiers of the IRE1ɑ/XBP1 signalling pathway [63–66]. This evidence concerns the gene XBP1 and cancer.